News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F): Simeprevir Data From Cosmos Study in Hepatitis C Patients Will be Presented as Late-Breaking Presentation at American Association for Study of Liver Diseases



10/7/2013 7:49:06 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Regulatory News:

Medivir AB (OMX: MVIR) announced that data from the phase IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead’s investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease has been accepted as a late-breaking oral presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). AASLD will take place November 1 to 5 in Washington, D.C.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES